Consequently, the development of ABCC5 inhibitors as a targeted therapy strategy may help slow down tumor cell proliferation, enhance chemotherapy efficacy (15), restore antitumor immune responses, and correct RNA splicing abnormalities, thereby overcoming chemotherapy resistance and improving patient prognosis (43). Here, ABCC5 is linked to neoplasm.